Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenyang
Clinical trial register · China

Clinical Trials in Shenyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shengjing Hospital47 General Hospital of Shenyang Military Region33 First Hospital of China Medical University19 AstraZeneca13 China Medical University, China11
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Shenyang

407 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
208
Shenyang, Tianjin
2026-10-20
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3
333
Guangzhou, Shenyang
2026-10-20
Not yet open
Cryoballoon Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
NCT07862972Paroxysmal Atrial Fibrillation (PAF)
Shenyang Northern Hospital
Observational
50
Shenyang
2026-10-15
Not yet open
Keverprazan vs Pantoprazole for the Treatment of ANVUGIB
NCT07776730Non-variceal Upper Gastrointestinal Bleeding
DrugsKeverprazan·Pantoprazole
General Hospital of Shenyang Military Region
Not applicable
908
Shenyang
2026-10-01
Not yet open
Haibo Shao
Phase 2
32
Shenyang
2026-10
Not yet open
General Hospital of Shenyang Military Region
Not applicable
208
Shenyang
2026-09-30
Not yet open
General Hospital of Shenyang Military Region
Not applicable
64
Shenyang
2026-09-25
Not yet open
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Not yet open
Shengjing Hospital
Phase 2
33
Shenyang
2026-09-01
Not yet open
General Hospital of Shenyang Military Region
Not applicable
466
Shenyang
2026-09
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Xi'an, Jinan
2026-09
Not yet open
China Medical University, China
Not applicable
332
Shenyang
2026-09
Not yet open
A Phase 2 Study of ABSK043 Combined With Osimertinib
NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
DrugsABSK043·Osimertinib
Abbisko Therapeutics Co, Ltd
Phase 2
72
Guangzhou, Harbin, Wuhan, Shenyang, Shanghai, Taiyuan, Hangzhou
2026-08-31
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
442
Guangzhou, Shenyang
2026-08-18
Not yet open
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
NCT07768085Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
Shengjing Hospital
Not applicable
40,000
Shenyang
2026-08-17
Not yet open
China Medical University, China
Not applicable
36
Shenyang
2026-08-10
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
130
Shenyang, Shanghai
2026-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Not yet open
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 1/2
120
Ha’erbin, Shenyang
2026-07-30
Recruiting
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 1
36
Beijing, Wuhan, Shenyang, Jinan
2026-07-16
Not yet open
Shengjing Hospital
Not applicable
44
Shenyang
2026-07-10
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
472
Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou
2026-07-03
Not yet open
Shengjing Hospital
Not applicable
54
Shenyang
2026-07-01
Not yet open
Peking University
Not applicable
480
Wuhu, Zhengzhou, Shenyang, Zibo, Shanghai, Hangzhou, Jinhua, Beijing
2026-07
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
66
Shenyang
2026-06-30
Recruiting
Shenyang Northern Hospital
Phase 4
110
Shenyang
2026-06-25
Recruiting
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
Liaoning Cancer Hospital & Institute
Not applicable
54
Shenyang
2026-06-18
Not yet open
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
DrugCrisugabalin
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Recruiting
China Medical University, China
Not applicable
60
Shenyang
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugCamrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Recruiting
Innatus Therapeutics (Shanghai) Co., Ltd.
Phase 1/2
24
Guangzhou, Shenyang, Beijing, Hangzhou, Shanghai, Taiyuan, Weifang, Wenzhou
2026-06-11
Recruiting
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
NCT07362966Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
Shenyang Northern Hospital
Phase 4
120
Shenyang
2026-06-08
Recruiting
Individualized Non-pharmacological Intervention for Bowel Preparation
NCT07684716Bowel Preparation for Colonoscopy
General Hospital of Shenyang Military Region
Not applicable
339
Shenyang
2026-06-08
Recruiting
Jie Liang
Not applicable
600
Beijing, Shenyang, Xining, Xi'an, Shanghai, Changzhi, Linfen, Yuncheng
2026-06-01
Recruiting
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Eye & ENT Hospital of Fudan University
Observational
70
Harbin, Changsha, Shenyang, Shanghai, Xi’an, Wenzhou
2026-06-01
Not yet open
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204Recurrent/Metastatic Head and Neck Cancer
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
128
Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu
2026-06
Recruiting
First Hospital of China Medical University
Phase 2
38
Shenyang
2026-05-20
Active, closed
First Hospital of China Medical University
Not applicable
6,800
Cangzhou, Suzhou, Panjin, Shenyang, Jinzhou, Tianjin
2026-05-14
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
General Hospital of Shenyang Military Region
Phase 2
122
Shenyang
2026-05-06
Recruiting
First Hospital of China Medical University
Observational
30
Shenyang
2026-05-01
Recruiting
First Hospital of China Medical University
Not applicable
210
Shenyang
2026-05-01
Not yet open
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Not yet open
Shenyang Medical College
Not applicable
60
Shenyang
2026-04-28
Recruiting
Daoyin Technique for Improving Exercise Endurance in IPF
NCT07019714Idiopathic Pulmonary Fibrosis
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Not applicable
236
Beijing, Zhengzhou, Shenyang
2026-04-22
Not yet open
Shenyang Medical College
Not applicable
214
Shenyang
2026-04-19
Not yet open
Shanghai Mabgeek Biotech.Co.Ltd
Phase 3
180
Shenyang
2026-04-17
Recruiting
magAssist, Inc.
Not applicable
204
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an
2026-04-09
Active, closed
A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors
NCT07749703Histologically or Cytologically Confirmed Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
346
Hefei, Shenyang, Jinan, Shanghai, Hangzhou
2026-03-31
By invitation
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
NCT07248722Esophageal and Gastric Varices, Liver Cirrhosis
DrugPantoprazole
General Hospital of Shenyang Military Region
Not applicable
208
Shenyang
2026-03-27
Recruiting
General Hospital of Shenyang Military Region
Phase 2
120
Shenyang
2026-03-25
Recruiting
General Hospital of Shenyang Military Region
Phase 2
198
Shenyang
2026-03-25
Recruiting
General Hospital of Shenyang Military Region
Not applicable
232
Shenyang
2026-03-24
Recruiting
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
NCT07309055Adolescents With Moderate-to-severe Atopic Dermatitis
DrugSHR-1819
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 3
201
Shenyang, Shanghai
2026-03-21
Recruiting
General Hospital of Shenyang Military Region
Not applicable
50
Shenyang
2026-03-20
Recruiting
Peking University
Not applicable
200
Beijing, Baoding, Shijiazhuang, Shenyang, Jinan
2026-03-20
Not yet open
Efficacy and Safety of Sanyong Jiedu Granules in Treating Lumps-Type Non-Lactational Mastiti
NCT07512648Plasmacytic Mastitis, Granulomatous Lobular Mastitis
Caigang Liu
Not applicable
210
Shenyang
2026-03-20
Not yet open
Lithotripsy Versus Balloon Angioplasty for Optimal Treatment of CAlcified Lesions With and Without Optical Coherence Tomography evaluatION
NCT07388030Coronary Artery Disease, Severe Coronary Artery Disease, Coronary Artery Calcification
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Not applicable
3,060
Shenyang
2026-03-20
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
282
Guangzhou, Shenyang
2026-03-19
Active, closed
AstraZeneca
Observational
146
Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming
2026-03-19
Recruiting
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
China Medical University, China
Not applicable
1,000
Shenyang
2026-03-18
Active, closed
Sanofi
Phase 3
59
Baotou, Beijing, Chengdu, Jinan, Jingzhou, Nanning, Shenyang, Taiyuan
2026-03-12
Recruiting
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
General Hospital of Shenyang Military Region
Not applicable
300
Shenyang
2026-03-04
Recruiting
Chuansheng Zhao
Phase 4
80
Shenyang
2026-03-02
Not yet open
Shenyang Northern Hospital
Not applicable
468
Shenyang
2026-03-01
Not yet open
Chuansheng Zhao
Phase 3
344
Shenyang
2026-03-01
Recruiting
First Hospital of China Medical University
Phase 4
10
Shenyang
2026-03
By invitation
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
NCT07613827Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
Shengjing Hospital
Not applicable
7,969
Shenyang
2026-02-24
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Active, closed
General Hospital of Shenyang Military Region
Not applicable
32
Shenyang
2026-02-01
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
DrugMontelukast
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Ha’erbin, Hefei, Hunan, Shenyang
2026-02-01
Recruiting
A Phase III Study of GS101 Injection to Dupixent®
NCT07386743Atopic Dermatitis (AD)
DrugDupilumab
Jiangsu Genscend Biopharmaceutical Co., Ltd
Phase 3
572
Shenyang
2026-01-29
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
General Hospital of Shenyang Military Region
Phase 2
200
Shenyang
2026-01-20
Recruiting
Biocells (Beijing) Biotech Co.,Ltd
Phase 3
1,112
Hengshui, Daqing, Nanyang, Meihekou, Shenyang, Xianyang, Linyi, Linfen
2026-01-19
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
Sanofi
Phase 3
160
Beijing, Chengdu, Dongguan, Guangzhou, Jiazhuang, Shenyang
2026-01-14
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Recruiting
General Hospital of Shenyang Military Region
Observational
800
Shenyang
2026-01-08
Recruiting
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
120
Lanzhou, Qinhuangdao, Shenyang, Yinchuan, Xi’an
2026-01-07
Recruiting
General Hospital of Shenyang Military Region
Not applicable
60
Shenyang
2026-01-02
Recruiting
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
NCT07311408Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
DrugsSHR-2554·Rivoceranib·Retlirafusp alfa
Jingdong Zhang
Phase 2
40
Shenyang
2026-01-01
Active, closed
A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts
NCT07339306Mammary Tumor, Nipple Discharge, Breast Ductal Carcinoma In Situ
The Fourth Affiliated Hospital of China Medical University
Not applicable
300
Shenyang
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
364
Chongqing, Foshan, Zhengzhou, Wuhan, Shenyang, Guilin, Xi’an
2026-01-01
Not yet open
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
NCT07354828Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
Shenyang Northern Hospital
Observational
3,500
Shenyang
2025-12-30
Recruiting
Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention
NCT07848152Transcatheter Mitral Valve Edge-to-Edge Repair System, Biodegradable Patent Foramen Ovale Closure Device
Shanghai Jiao Tong University School of Medicine
Observational
2,200
Lanzhou, Guangzhou, Zhengzhou, Wuhan, Shenyang, Jinan, Chengdu, Kunming
2025-12-30
Recruiting
Shenyang Medical College
Not applicable
62
Shenyang
2025-12-29
Not yet open
First Hospital of China Medical University
Observational
1,000
Shenyang
2025-12-25
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
170
Shenyang
2025-12-10
Not yet open
XueMei Guo
Not applicable
120
Shenyang
2025-12-10
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Luoyang, Shenyang, Wenzhou, Beijing
2025-12-02
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
Shenyang Medical College
Not applicable
56
Shenyang
2025-11-23
Recruiting
A Study of GensSci098 in Subjects With Graves' Disease
NCT07286656Safety, Tolerability, GenSci098, Graves Disease
DrugGenSci098
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
24
Shenyang
2025-11-21
Recruiting
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Shenyang Medical College
Not applicable
56
Shenyang
2025-11-19
Recruiting
Shenyang Medical College
Not applicable
48
Shenyang
2025-11-19
Recruiting
General Hospital of Shenyang Military Region
Observational
2,800
Shenyang
2025-11-19
Recruiting
General Hospital of Shenyang Military Region
Phase 3
870
Shenyang
2025-11-13
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Recruiting
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
Health Behavior Change in High-Risk Colorectal Cancer Individuals
NCT07262840Health Behavior, Colorectal Neoplasms, Primary Prevention/Methods
China Medical University, China
Not applicable
80
Shenyang
2025-11-10
Recruiting
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase 2
200
Shenyang
2025-11-05
Active, closed
Pai Pang
Not applicable
80
Shenyang
2025-10-28
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2
184
Hangzhou, Shenyang
2025-10-27
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
740
Shenyang, Shanghai
2025-10-23
Recruiting
China Medical University, China
Phase 2
36
Shenyang
2025-10-15
Recruiting
First Hospital of China Medical University
Not applicable
80
Shenyang
2025-10-01
Recruiting
CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
NCT07193667Relapsed/Refractory Autoimmune Diseases
ShenZhen Cell Valley
Not applicable
3
Shenyang
2025-10
Recruiting
Shengjing Hospital
Observational
30
Shenyang
2025-09-25
Recruiting
Yi Tian
Phase 1
30
Shenyang
2025-09-11
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
111
Shenyang
2025-09-10
Recruiting
Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
NCT07160491STEMI - ST Elevation Myocardial Infarction
Shenyang Northern Hospital
Not applicable
3,356
Shenyang
2025-09-08
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
General Hospital of Shenyang Military Region
Not applicable
210
Shenyang
2025-09-02
Not yet open
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
170
Shenyang
2025-08-26
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
600
Shenyang, Shanghai
2025-08-18
Recruiting
Xuanwu Hospital, Beijing
Observational
6,000
Beijing, Hainan, Ningxiang, Shenyang, Shenzhen, Yichun
2025-08-15
Active, closed
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
266
Shenyang
2025-08-11
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Not yet open
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Recruiting
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)
Xueyan Zhao
Observational
12,154
Zhengzhou, Shenyang, Beijing
2025-08-01
Not yet open
Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
NCT07088744Gastric Cancer (Diagnosis), Gastric High-grade Intraepithelial Neoplasia, Gastric Low-grade Intraepithelial Neoplasia, Gastritis
Changhai Hospital
Observational
169
Nanning, Shenyang, Chengdu, Shanghai
2025-07-30
Active, closed
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
12
Shenyang
2025-07-28
Recruiting
Xiujuan Qu
Phase 2
20
Shenyang
2025-07-15
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
First People's Hospital of Shenyang
Not applicable
206
Shenyang
2025-07-07
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
Liaoning Cancer Hospital & Institute
Phase 2
120
Shenyang
2025-07-01
Recruiting
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
240
Chongqing, Shenzhen, Haikou, Hohhot, Shenyang, Qingdao, Tacheng
2025-07-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Recruiting
General Hospital of Shenyang Military Region
Not applicable
174
Shenyang
2025-06-24
Recruiting
General Hospital of Shenyang Military Region
Not applicable
232
Shenyang
2025-06-24
Active, closed
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Recruiting
Boehringer Ingelheim
Phase 2
300
Chengdu, Shanghai, Shenyang, Shijiazhuang, Taiyuan
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2025-06-04
Recruiting
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Active, closed
The Fourth Affiliated Hospital of China Medical University
Observational
300
Shenyang
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi
2025-06-01
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
DrugsAK129·Penpulimab·Cis-platinum·Cetuximab
Akeso
Phase 1/2
230
Shenyang
2025-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
360
Shenyang
2025-05-16
Recruiting
China Medical University, China
Phase 2
40
Shenyang
2025-05-12
Not yet open
China Medical University, China
Phase 4
31
Shenyang
2025-04-30
Active, closed
First Hospital of China Medical University
Not applicable
45
Shenyang
2025-04-25
Recruiting
China Medical University, China
Not applicable
70
Shenyang
2025-04-21
By invitation
Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants
NCT07460297Postoperative Seroma Rate, Drainage Tube Removal Time, and Capsular Contracture Rate, Seroma Following Procedure
DrugPovidone-iodine
Jianyi Li
Not applicable
100
Shenyang
2025-04-16
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugSIRT
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xi’an, Chengdu
2025-04-15
Recruiting
General Hospital of Shenyang Military Region
Not applicable
1,600
Shenyang
2025-04-13
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
Shanghai Chest Hospital
Not applicable
162
Shenyang, Shanghai, Huizhou
2025-04-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
Active, closed
Xiujuan Qu
Not applicable
120
Shenyang
2025-03-20
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Observational
120
Shenyang
2025-03-12
Recruiting
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Not yet open
The Second Affiliated Hospital of Dalian Medical University
Phase 2
40
Dalian, Shenyang
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Tianjin Institute of Pharmaceutical Research Co., Ltd
Phase 2
600
Shenyang, Beijing
2025-02-21
Recruiting
General Hospital of Shenyang Military Region
Not applicable
100
Shenyang
2025-02-19
Recruiting
First Hospital of China Medical University
Observational
1,516
Shenyang
2025-02-17
Recruiting
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
NCT06717750Advanced Malignant Solid Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1
102
Beijing, Shenyang
2025-02-13
Recruiting
Yufan Wang
Observational
2,920
Lanzhou, Shanghai, Shenyang
2025-02-01
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189Marginal Zone Lymphoma(MZL)
DrugOrelabrutinib
Ruijin Hospital
Phase 2
145
Shanghai, Shenyang, Beijing
2025-01-23
Recruiting
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
NCT06830018Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment
DrugNano-crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
76
Shenyang
2025-01-23
Recruiting
Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury
NCT07106060SCI - Spinal Cord Injury, Motor Imagery, Brain-Computer Interfaces
Shengjing Hospital
Not applicable
36
Shenyang
2025-01-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Recruiting
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
NCT06779058Chronic Hepatitis B, Liver Fibrosis
Shengjing Hospital
Observational
600
Shenyang
2025-01-01
Recruiting
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
JiaRay Group
Phase 1
94
Harbin, Shenyang
2024-12-31
Recruiting
The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation
NCT07085650Atrial Fibrillation (AF), Mitral Regurgitation, Tricuspid Regurgitation
First Hospital of China Medical University
Observational
2,000
Shenyang
2024-12-30
By invitation
Caigang Liu
Not applicable
2,000
Shenyang
2024-12-30
Recruiting
Shengjing Hospital
Not applicable
60
Shenyang
2024-12-25
Recruiting
Shengjing Hospital
Not applicable
44
Shenyang
2024-12-15
Recruiting
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Not yet open
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
NCT06666166Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
Yunpeng Liu
Phase 2
28
Shenyang
2024-12
Active, closed
Queen's University, Belfast
Not applicable
10,000
Shenyang, Yinchuan
2024-11-28
Recruiting
Jianbin Bi
Phase 2
40
Shenyang
2024-11-27
Recruiting
Shengjing Hospital
Observational
1,000
Shenyang
2024-11-15
Recruiting
Shengjing Hospital
Observational
840
Shenyang
2024-11-15
Active, closed
Liaoning Chengda Biotechnology CO., LTD
Phase 4
250
Shenyang
2024-11-14
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Folfox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
By invitation
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NCT07059819Cervical Intraepithelial Neoplasia (CIN), Human Papillovirus
First Hospital of China Medical University
Not applicable
400
Shenyang
2024-11-02
By invitation
Sleep Improvement Therapy Affects Pregnancy Outcomes in Chinese Singletons and Twins by Improving Sleep Quality
NCT06687044Gestational Diabetes, Hypertension in Pregnancy, Preterm Labor, NICU Infants
Jun Wei
Not applicable
300
Shenyang
2024-11-01
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Recruiting
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Recruiting
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
NCT06577519Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
DrugClopidogrel
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3
1,000
Shenyang
2024-09-06
Active, closed
Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
NCT06031402Acute Upper Gastrointestinal Bleeding, Acute Variceal Bleeding
General Hospital of Shenyang Military Region
Not applicable
368
Shenyang
2024-09-04
Recruiting
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
Shengjing Hospital
Phase 2
93
Shenyang
2024-08-23
Active, closed
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3
574
Harbin, Shenyang
2024-08-15
Recruiting
Yunpeng Liu
Not applicable
38
Shenyang
2024-08-09
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
124
Shenzhen, Shenyang
2024-08-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
General Hospital of Shenyang Military Region
Not applicable
60
Shenyang
2024-08-01
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
First Hospital of China Medical University
Not applicable
400
Shenyang
2024-07-10
Recruiting
Shenyang Northern Hospital
Not applicable
3,490
Shenyang
2024-07-02
Recruiting
General Hospital of Shenyang Military Region
Observational
800
Shenyang
2024-07-02
Recruiting
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Not yet open
Yunpeng Liu
Not applicable
30
Shenyang
2024-07-01
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Active, closed
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Shengjing Hospital
Observational
150
Shenyang
2024-06-06
Recruiting
General Hospital of Shenyang Military Region
Not applicable
300
Shenyang
2024-06-01
Active, closed
SGLT2-inhibitors on PC-AKI
NCT06491953Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
Shenyang Northern Hospital
Observational
3,600
Shenyang
2024-06-01
Active, closed
Hoffmann-La Roche
Observational
1,000
Shantou, Luoyang, Shiyan, Xuzhou, Fushun, Panjin, Shenyang, Weifang
2024-05-09
By invitation
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1
12
Shenyang
2024-05-07
Active, closed
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Active, closed
First Hospital of China Medical University
Phase 1/2
30
Shenyang
2024-04-01
Not yet open
OCT or Angiography Guided De-escalation of DAPT
NCT06339021Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage
Shenyang Northern Hospital
Early Phase 1
80
Shenyang
2024-04-01
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Recruiting
Liaoning Cancer Hospital & Institute
Observational
240
Shenyang
2024-03-21
Recruiting
First Hospital of China Medical University
Not applicable
150
Shenyang
2024-03-15
Recruiting
Prime Gene Therapeutics Co., Ltd.
Phase 3
472
Shenyang
2024-03-15
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Active, closed
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
Clinical Outcomes of Patients With Coronary Artery Disease
NCT06216847Coronary Heart Disease (CHD)
Shenyang Northern Hospital
Observational
10,000
Shenyang
2024-02-21
Not yet open
Shengjing Hospital
Phase 2
128
Shenyang
2024-02-10
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Recruiting
General Hospital of Shenyang Military Region
Phase 4
1,440
Shenyang
2024-02-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Caigang Liu
Phase 3
30
Shenyang
2024-02-01
Recruiting
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Active, closed
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Recruiting
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
General Hospital of Shenyang Military Region
Not applicable
600
Shenyang
2024-01-10
Recruiting
First Hospital of China Medical University
Observational
600
Fuzhou, Dalian, Shenyang, Chengdu
2024-01-01
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Active, closed
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Shengjing Hospital
Observational
50
Shenyang
2023-12-24
Recruiting
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K
NCT06278974Myopia, Cost-effectiveness Analysis, Quality of Life
He Eye Hospital
Observational
90
Shenyang
2023-11-10
Recruiting
First Hospital of China Medical University
Not applicable
352
Shenyang
2023-11-01
Not yet open
China Medical University, China
Phase 2
30
Shenyang
2023-11-01
Active, closed
Sinovac Biotech Co., Ltd
Phase 4
1,092
Shenyang
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
Shengjing Hospital
Phase 2
136
Shenyang
2023-09-26
Active, closed
Shengjing Hospital
Not applicable
24
Shenyang
2023-09-25
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
By invitation
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yan’an, Kunming, Beijing
2023-08-21
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
NCT05824923Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
Pulnovo Medical (Wuxi) Co., Ltd.
Phase 3
264
Shenyang
2023-08-14
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
Shengjing Hospital
Observational
1,000
Shenyang
2023-07-18
Active, closed
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Active, closed
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
63
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Active, closed
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Active, closed
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Recruiting
Shengjing Hospital
Phase 2
65
Shenyang
2023-03-16
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Active, closed
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Recruiting
GeneCradle Inc
Phase 1/2
18
Beijing, Shenyang, Suzhou
2023-02-25
Recruiting
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Recruiting
Xijing Hospital of Digestive Diseases
Phase 2/3
104
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an, Yan’an
2023-02-17
Recruiting
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke
NCT05897645Stroke, Intracranial Atherosclerosis, High Resolution Magnetic Resonance Imaging
General Hospital of Shenyang Military Region
Observational
2,110
Shenyang
2023-01-19
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang
2023-01-16
Recruiting
TR64 in Patients With Advanced Solid Tumors
NCT05649345Advanced Solid Tumor
Tarapeutics Science Inc.
Phase 1
19
Bengbu, Shenyang
2023-01-12
Recruiting
Shengjing Hospital
Not applicable
20
Shenyang
2023-01-01
Recruiting
Shengjing Hospital
Phase 2
236
Shenyang
2022-12-20
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Recruiting
First Hospital of China Medical University
Not applicable
300
Shenyang
2022-12-07
Active, closed
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Recruiting
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
DrugMufemilast
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Recruiting
Shengjing Hospital
Not applicable
300
Shenyang
2022-10-19
Recruiting
Multifrequency MRE in Evaluation of Chronic Kidney Diseases
NCT06202235Chronic Kidney Disease (CKD)
Shengjing Hospital
Observational
200
Shenyang
2022-10-10
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Active, closed
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Recruiting
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
NCT06205992Cirrhosis, Liver Portal Hypertension
Shengjing Hospital
Observational
100
Shenyang
2022-08-16
Recruiting
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
NCT05475015Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease
Shengjing Hospital
Observational
150
Shenyang
2022-08-16
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Shengjing Hospital
Observational
200
Shenyang
2022-08-01
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Active, closed
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Recruiting
Shengjing Hospital
Observational
100
Shenyang
2022-06-14
Active, closed
Caigang Liu
Phase 2/3
136
Shenyang
2022-05-23
By invitation
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
Recruiting
Fingolimod for Type 2 Diabetes Mellitus
NCT05307731Diabetes Mellitus, Type 2
DrugFingolimod
General Hospital of Shenyang Military Region
Phase 4
40
Shenyang
2022-03-15
Active, closed
Shanghai Shenqi Medical Technology Co., Ltd
Not applicable
125
Shenyang
2022-03-07
Recruiting
Shengjing Hospital
Not applicable
500
Shenyang
2022-03-01
Recruiting
Shengjing Hospital
Phase 2
12
Shenyang
2022-02-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Recruiting
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Not yet open
Liaoning Cancer Hospital & Institute
Phase 2
45
Shenyang
2022-01-01
Active, closed
AstraZeneca
Phase 3
145
Beijing, Guangzhou, Shenyang
2021-11-19
Recruiting
Shengjing Hospital
Not applicable
100
Shenyang
2021-11-01
Active, closed
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
By invitation
Shanghai Shenqi Medical Technology Co., Ltd
Not applicable
118
Shenyang
2021-10-15
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Recruiting
Shengjing Hospital
Phase 2
30
Shenyang
2021-08-01
Not yet open
Shengjing Hospital
Phase 3
450
Shenyang
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Recruiting
Shengjing Hospital
Phase 4
110
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Shengjing Hospital
Phase 3
1,498
Shenyang
2021-07-19
Recruiting
Shengjing Hospital
Observational
1,000
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Recruiting
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Active, closed
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Recruiting
Psychological Screening and Nursing of Twin Pregnancy
NCT05182541Twin; Complicating Pregnancy, Psychology
Shengjing Hospital
Not applicable
100
Shenyang
2021-03-01
Active, closed
Jilin University
Not applicable
350
Changchun, Beijing, Chongqing, Guangzhou, Shanghai, Shenyang
2021-01-27
Recruiting
Yu Shi
Observational
1,500
Shenyang
2021-01-21
Recruiting
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
NCT05098769Pulmonary Embolism and Thrombosis, Deterioration, Clinical
Shengjing Hospital
Observational
300
Shenyang
2021-01-18
Active, closed
Amgen
Phase 3
135
Hohhot, Beijing, Guandong, Shang’ai, Shenyang, Wuhan
2020-12-04
Recruiting
Hui-Sheng Chen
Not applicable
30
Shenyang
2020-12-01
Recruiting
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
NCT04664933Stroke, Ischemic, Intravascular Thrombosis, Mechanical Thrombectomy
Hui-Sheng Chen
Not applicable
30
Shenyang
2020-12-01
Active, closed
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Recruiting
Yu Shi
Observational
200
Shenyang
2020-10-09
Recruiting
MRE for Diagnosis of Pancreatic Masses
NCT06526442Pancreatic Neoplasm, Magnetic Resonance Imaging
Yu Shi
Observational
200
Shenyang
2020-10-09
Active, closed
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Active, closed
PharmaEssentia
Phase 3
174
Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan
2020-08-25
Recruiting
Ruijin Hospital
Observational
1,000
Beijing, Hanzhong, Cangzhou, Shijiazhuang, Qingdao, Shanghai, Shenyang
2020-07-30
Active, closed
Shengjing Hospital
Phase 2
89
Shenyang
2020-07-27
Active, closed
Actelion
Phase 3
935
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin
2020-06-30
Active, closed
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
AstraZeneca
Phase 2
452
Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou
2020-06-03
Active, closed
GlaxoSmithKline
Phase 3
494
Beijing, Jinan, Shenyang
2020-05-07
Active, closed
AbbVie
Phase 3
56
Beijing, Guangzhou, Shenzhen, Shenyang, Shanghai
2020-02-04
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
Actelion
Phase 3
138
Beijing, Guangzhou, Qingdao, Shanghai, Shenyang
2020-01-16
Recruiting
Hui-Sheng Chen
Not applicable
30
Shenyang
2019-12-15
Recruiting
Shengjing Hospital
Observational
500
Shenyang
2019-10-01
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Not yet open
Shengjing Hospital
Phase 4
120
Shenyang
2019-06-01
Active, closed
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Recruiting
Shengjing Hospital
Observational
1,500
Shenyang
2019-02-01
Recruiting
General Hospital of Shenyang Military Region
Phase 4
100
Shenyang
2018-12-01
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
AbbVie
Phase 3
1,533
Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai
2018-08-09
Recruiting
General Hospital of Shenyang Military Region
Observational
1,875
Shenyang
2018-08-01
Recruiting
Birth Cohort Study of China Medical University
NCT03561766Twin; Complicating Pregnancy, Advanced Maternal Age Pregnancy, Scarred Uterus, Overweight and Obesity
Shengjing Hospital
Observational
1,000
Shenyang
2018-06-15
Active, closed
First Hospital of China Medical University
Not applicable
33,995
Shenyang
2018-05-08
Active, closed
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
Shengjing Hospital
Observational
626
Shenyang
2017-05-09
Active, closed
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Recruiting
Shengjing Hospital
Not applicable
100
Shenyang
2017-01-01
Active, closed
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Recruiting
First Hospital of China Medical University
Observational
1,000
Shenyang
2012-11-14
Recruiting
Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
NCT05482269Pulmonary Embolism and Thrombosis, Deterioration, Clinical, Artificial Intelligence
Shengjing Hospital
Observational
2,000
Shenyang
2011-01-01
Active, closed
An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients
NCT05481242Pulmonary Embolism and Thrombosis, Deterioration, Clinical
Shengjing Hospital
Observational
2,000
Shenyang
2011-01-01
Rows per page Showing 1–407 of 407
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/shenyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 407 of those studies with a site in Shenyang.

How many clinical trials are recruiting in Shenyang?

249 of the 407 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 48 have not yet opened recruitment, 100 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shenyang), 407 studies
PhaseStudiesRecruitingShare
Not applicable1006024.6%
Observational755918.4%
Phase 3743018.2%
Phase 2663716.2%
Phase 134258.4%
Phase 1/234248.4%
Phase 41593.7%
Phase 2/3852%
Early Phase 1100.2%

Most active sponsors

Lead sponsors with the most studies (Shenyang)
Lead sponsorStudiesRecruiting
Shengjing Hospital4735
General Hospital of Shenyang Military Region3326
First Hospital of China Medical University1913
AstraZeneca135
China Medical University, China117
Shenyang Northern Hospital105
Sanofi92
AbbVie81
Novartis Pharmaceuticals84
BeOne Medicines65
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.